Efficacy of 38% Silver Diamine Fluoride (SDF) versus Atraumatic Restorative Treatment (ART) in Arresting Dental Caries in Paediatric Patients: A Systematic Review and Meta-Analysis.

Eur J Paediatr DentApr 1, 2026 (epub)
Clinical ResearchPediatrics

A Alqadi, L Qubbaj, B Saleh et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed whether 38% silver diamine fluoride (SDF) arrests dental caries in paediatric patients compared with atraumatic restorative treatment (ART) or placebo. The review included six randomised controlled trials identified through database searches and used a random-effects model. The authors concluded that 38% SDF is effective in halting caries and slightly outperforms ART; both interventions may be considered for paediatric patients. The abstract provides no pooled effect estimate or other quantitative comparison of treatment outcomes.

Key findings

  • Six randomised controlled trials met the review’s inclusion criteria.
  • The authors concluded that 38% SDF halts caries in paediatric patients and slightly outperforms ART.
  • The review concluded that both SDF and ART may be considered for paediatric patients.

Why it matters

Caries-arresting approaches are relevant to paediatric care, and this review synthesises trial evidence comparing a topical intervention with a restorative approach. Its conclusion suggests both may have a role, while the lack of a reported pooled effect estimate in the abstract makes the size of any advantage difficult to judge.

What to keep in mind

Only six trials were included. The authors call for more standardised research with extended follow-up; the abstract does not report a pooled effect estimate.

Source

Published in Eur J Paediatr Dent. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.